Meitav Investment House Ltd. Raises Stock Position in Cellebrite DI Ltd. $CLBT

Meitav Investment House Ltd. increased its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 34.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,954,846 shares of the company’s stock after acquiring an additional 500,000 shares during the period. Meitav Investment House Ltd. owned approximately 0.78% of Cellebrite DI worth $26,938,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI in the 3rd quarter worth about $40,000. CWM LLC boosted its position in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares in the last quarter. First Horizon Corp grew its stake in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the last quarter. Finally, Vestcor Inc acquired a new stake in Cellebrite DI in the 3rd quarter valued at about $70,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CLBT shares. DA Davidson initiated coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price for the company. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Needham & Company LLC dropped their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Insider Buying and Selling

In related news, CEO Thomas E. Hogan sold 103,188 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 116,457 shares of company stock valued at $1,795,835. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Stock Performance

CLBT stock traded up $0.25 during trading on Tuesday, hitting $16.86. The stock had a trading volume of 445,582 shares, compared to its average volume of 1,996,110. The stock has a market cap of $4.21 billion, a price-to-earnings ratio of 60.10, a price-to-earnings-growth ratio of 1.94 and a beta of 1.17. The company’s 50 day moving average price is $13.48 and its two-hundred day moving average price is $14.57. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.